We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Combined Molecular Test Distinguishes Benign Pancreatic Lesions

By LabMedica International staff writers
Posted on 05 Jul 2017
When performed in tandem, two molecular biology laboratory tests distinguish, with near certainty, pancreatic lesions that mimic early signs of cancer but are completely benign. More...
Serous cystic neoplasms (SCNs) have no malignant potential, but can mimic the following premalignant mucinous cystic lesions: mucinous cystic neoplasm and intraductal papillary mucinous neoplasm (IPMN).

Patients with SCN undergo imaging or other surveillance every six months to spot changes indicative of cancer, or they undergo an operation to remove part of the gland as a precaution because SCN are difficult to find using standard diagnostic methods. More than 60% of SCN are not predicted preoperatively and 50% to 70% are missed or incorrectly diagnosed on radiology scans.

Medical scientists at the Indiana University School of Medicine (Indianapolis, IN, USA) included in their study 149 patients who underwent an operation to remove a pancreatic cystic lesion and 26 of these patients had SCN. The diagnosis of each surgical specimen was confirmed by pathologic examination, and samples of pancreatic fluid from all patients were tested for Vascular endothelial growth factor A (VEGF-A) and Carcinoembryonic antigen (CEA) according to testing protocols for enzyme-linked biochemical analysis of fluids (ELISA).

The team discovered that tests for each of these proteins in pancreatic cyst fluid accurately distinguished SCN from other types of pancreatic lesions. In the present study, VEGF-A with a threshold of greater than 5,000 pg/mL alone, singled out SCN with a sensitivity of 100% and specificity of 83.7%, and CEA with a threshold of equal to or less than10 ng/mL, had a 95.5% sensitivity and 81.5% specificity. Together, however, the tests approached the gold standard of pathologic testing: The combination had a sensitivity of 95.5% and specificity of 100% for SCN. Authors of the study concluded that results of the VEGF-A/CEA test could have prevented 26 patients from having unnecessary surgery.

C. Max Schmidt, MD, PhD, FACS, a professor of surgery and biochemical/molecular biology and senior study author, said, “Every day, surgeons follow patients who have pancreatic cysts that have no risk of cancer but are still worrisome. They perform surgery or conduct diagnostic tests just to make sure they're not wrong. With VEGF-A and CEA, we believe we may have invented a test that can help that group of patients who don't have a risk of cancer get off the testing cycle and avoid surgery which, in and of itself, has a risk of mortality or complications.” The study was published in the July 2017 issue of the Journal of the American College of Surgeons.

Related Links:
Indiana University School of Medicine


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.